ArticlePharmacoepidemiology and drug safety2013
Completeness of prescription information in US commercial claims databases.
Article in Pharmacoepidemiology and drug safety, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- A systematic review of methods for determining cross-sectional active medications using pharmacy databases.Pharmacoepidemiology and drug safety · 2019Pooled it
- Comparison of a new 3-item self-reported measure of adherence to medication with pharmacy claims data in patients with cardiometabolic disease.American heart journal · 2020Trial
- Rationale and design of the Study of a Tele-pharmacy Intervention for Chronic diseases to Improve Treatment adherence (STIC2IT): A cluster-randomized pragmatic trial.American heart journal · 2016Trial
- Clinical Characteristics, Healthcare Utilization, and Treatment Patterns Among People Living with HIV by Antiretroviral Therapy Use in the USA, 2021-2024.Infectious diseases and therapy · 2026Article
- Antidepressant use among American adults in a 50-state survey.BMJ mental health · 2026Article
- Validating claims-based definitions for deprescribing: Bridging the gap between clinical and administrative data.Pharmacoepidemiology and drug safety · 2024Article
- Trends in the Use of Oral Anticoagulants for Adults With Venous Thromboembolism in the US, 2010-2020.JAMA network open · 2023Article
- Comparison of measures of medication adherence from pharmacy dispensing and insurer claims data.Health services research · 2022Article
- Drug exposure misclassification in pharmacoepidemiology: Sources and relative impact.Pharmacoepidemiology and drug safety · 2021Article
- Factors associated with primary nonadherence to newly initiated direct oral anticoagulants in patients with nonvalvular atrial fibrillation.Journal of managed care & specialty pharmacy · 2021Observational
- Quantifying cumulative anticholinergic and sedative drug load among US Medicare Beneficiaries.Pharmacoepidemiology and drug safety · 2021Article
- Real-world on-treatment and initial treatment absolute risk differences for dabigatran vs warfarin in older US adults.Pharmacoepidemiology and drug safety · 2020Article
- Effect of Initiating Cardiac Rehabilitation After Myocardial Infarction on Subsequent Hospitalization in Older Adults.Journal of cardiopulmonary rehabilitation and prevention · 2020Article
- Comparison of Pharmacy Database Methods for Determining Prevalent Chronic Medication Use.Medical care · 2019Article
- Association of Region and Hospital and Patient Characteristics With Use of High-Intensity Statins After Myocardial Infarction Among Medicare Beneficiaries.JAMA cardiology · 2019Article
- Identifying Smoking Status and Smoking Cessation Using a Data Linkage Between the Kentucky Cancer Registry and Health Claims Data.JCO clinical cancer informatics · 2019Article
- Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review.BMC medical research methodology · 2019Article
- Truven Health Analytics MarketScan Databases for Clinical Research in Colon and Rectal Surgery.Clinics in colon and rectal surgery · 2019Review
- Patchwork of contrasting medication cultures across the USA.Nature communications · 2018Article
- Development of an algorithm to link electronic health record prescriptions with pharmacy dispense claims.Journal of the American Medical Informatics Association : JAMIA · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
purposePharmacy commercial claims databases are widely used for pharmacoepidemiologic research. However, concerns have been raised that these databases may not fully capture claims for generic medications as a result of patients filling outside the context of their insurance. This has implications for many research activities and quality improvement programs. We sought to estimate the percentage of missing prescriptions in US commercial claims data using a novel design.
methodsUsing a large US commercial insurance database, we examined the completeness of warfarin prescription claims among patients with atrial fibrillation receiving regular medical follow-up and testing to manage warfarin dosing. We examined 14 different 6-month cross sections. Each cross section was treated independently to identify patients with at least two outpatient diagnoses of atrial fibrillation, two international normalized ratio tests, and one pharmacy claim. Trends in the percentage of patients with prescription claims for generic and branded warfarin were compared by year and 6-month periods using chi-square tests and generalized linear models adjusting for patient characteristics.
resultsOut of 111 170 patients, the percentage of patients with any warfarin drug decreased slightly from 91.7% (95% CI: 91.0, 92.4) in early 2003 to 87.1% (95% CI: 86.7-87.6) in late 2009 (χ(2) = 93.8, p < 0.0001). Over the same interval, the proportion of patients with generic warfarin exposure appearing increased significantly, whereas the proportion of patients with branded warfarin exposure decreased significantly.
conclusionsOur study supports the possibility that some prescriptions may not be captured in US commercial insurance databases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.